Gilde Healthcare participates in EUR 36.6M financing round of cardiovascular company Sanifit - Gilde Healthcare

Gilde Healthcare participates in EUR 36.6M financing round of cardiovascular company Sanifit

September 8, 2015

Utrecht, The Netherlands and Palma de Mallorca, Spain – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, today announces that it has raised €36.6M in a late stage Series C financing round. The company is focused on the development of SNF472, a promising drug for the treatment of cardiovascular diseases linked to calcification in patients with End Stage Renal Disease (ESRD) undergoing haemodialysis.
Gilde Healthcare invested alongside a syndicate of international investors.

With the proceeds from this financing round Sanifit will advance its lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis. SNF472 has shown significant efficacy data in more than 20 preclinical studies and excellent safety and tolerability data in a phase Ia clinical trial in healthy volunteers. SNF472 is currently concluding a phase Ib/IIa pharmacology study in haemodialysis patients.

ESRD patients treated with dialysis experience higher rates of serious cardiovascular adverse events  and  mortality  as  a  consequence  of  accelerated  progression  of  cardiovascular calcification. Half of the mortality in dialysis patients is from cardiovascular complications. Calciphylaxis is the most severe form of cardiovascular calcification. It is a devastating rare disease that affects up to 4% of dialysis patients and has an overall mortality rate of about 80%. There are approximately 2.5 million dialysis patients worldwide with no effective treatment for this medical condition. ESRD represents a market opportunity of over €2Bn.

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, US) is a European fund manager specialized in fast growing private healthcare companies. Since 2001 Gilde Healthcare raised EUR 600M in dedicated funds across two business lines: Healthcare Technologies and Healthcare Services. The Gilde Healthcare Technology funds invest growth and later-stage capital in businesses active in digital health, medical technologies and therapeutics, both in Europe and the US. The Gilde Healthcare Services funds participate in lower mid-market service providers in the Benelux and Germany. For more information please visit www.gildehealthcare.com

Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives

Big Health, creators of the leading digital treatments for mental health, has appointed five executives to its senior leadership team as the company enters the next phase in the growth of its business. This follows...
January 12, 2023

Gilde Healthcare company Volta medical secures €36M in Series B funding

Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding,...
January 5, 2023

Gilde Healthcare company Adcendo Aps Announces License Agreement with Duality Biologics on Next-generation ADC Platform

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Adcendo ApS (“Adcendo”), a...
January 5, 2023